Amgen Inc (AMGN.OQ)
109.45USD
4:00pm EDT
$1.16 (+1.07%)
$108.29
$109.60
$109.88
$108.47
887,621
1,155,601
$114.95
$80.34
About
Overall
| Beta: | 0.51 |
| Market Cap (Mil.): | $81,214.96 |
| Shares Outstanding (Mil.): | 749.98 |
| Dividend: | 0.47 |
| Yield (%): | 1.74 |
Financials
| AMGN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 18.21 | 47.13 | 37.76 |
| EPS (TTM): | 5.95 | -- | -- |
| ROI: | 9.97 | -2.58 | 18.76 |
| ROE: | 23.03 | -2.66 | 19.59 |
Amgen profit tops Wall Street view; rebounds from first quarter
- Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.
UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr
July 30 - Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.
Amgen profit tops Wall Street view; rebounds from first quarter
- Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.
Amgen profit ex-items tops Wall Street view; rebounds after 1st qtr
July 30 - Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.
Exclusive: Amgen lines up BofA, JPM, Barclays to finance Onyx deal -sources
NEW YORK - Amgen Inc, the world's largest biotechnology company, has lined up Bank of America Corp, JPMorgan Chase & Co and Barclays Plc to finance a potential deal for Onyx Pharmaceuticals Inc, according to three people familiar with the matter.
DEALTALK-Biotech takeover interest more fad than fashion
July 19 - Investors betting on a wave of big biotechnology deals following Amgen Inc's $10 billion bid for Onyx Pharmaceuticals Inc may well be disappointed.
Exclusive: Pfizer not moving forward with Onyx bid: sources
NEW YORK - Pfizer Inc decided not to pursue a bid for Onyx Pharmaceuticals Inc this week, according to two people familiar with the matter, leaving Amgen Inc in the front position to buy the cancer drugmaker.
Initial takeover bids for Onyx seen as soon as this week: sources
NEW YORK - Onyx Pharmaceuticals Inc is expected to receive initial takeover bids as soon as this week after attracting interest from a few drugmakers, including Amgen Inc , according to several people familiar with the matter.
UPDATE 2-Initial takeover bids for Onyx seen as soon as this week-sources
NEW YORK, July 16 - Onyx Pharmaceuticals Inc is expected to receive initial takeover bids as soon as this week after attracting interest from a few drugmakers, including Amgen Inc, according to several people familiar with the matter.
Initial takeover bids for Onyx seen as soon as this week -sources
NEW YORK, July 16 - Onyx Pharmaceuticals Inc is expected to receive first-round offers as soon as this week after attracting takeover interest from a few drugmakers including Amgen Inc, according to several people familiar with the matter.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| Hospira, Inc. (HSP.N) | $42.03 | +1.33 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Shire PLC (SHP.L) | 2,440.00p | +38.00 |
| Shire PLC (3159084.L) | -- | -- |
| Bayer AG (BAYGn.DE) | €89.43 | +2.08 |
| Bayer AG (BAYE.F) | -- | -- |
| CHUGAI PHARMACEUTICAL CO., LTD. (4519.T) | ¥1,988 | +43.00 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 13,920.00₪ | -200.00 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$138.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

